Please join us this Thursday, July 12, 2018 from 09:30 – 11:00 EDT (15:30 – 17:00 CEST) for an exciting webinar presented by the endTB team, BDQ- and DLM-containing multidrug-regimens achieve excellent interim treatment response without safety concerns.
This webinar will be presented by Drs. Molly Franke (Partners in Health), Cathy Hewison (Médecins Sans Frontières) and Palwasha Khan (Interactive Research and Development). They will report on the endTB interim analyses of more than 1200 patients who started MDR-TB treatment regimens containing bedaquiline and/or delamanid between 1 April 2015 and 30 June 2017 in 15 countries. They will present preliminary efficacy analyses of delamanid and injectables used in multidrug regimens. Safety results will bedaquiline and delamanid (particularly QT interval prolongation), linezolid and injectables will also be shared.
To join the event as an attendee
1. Go to https://hms.webex.com/hms/onstage/g.php?MTID=e38385f6c41565906ec06d62939588543
2. Click “Join Now”.——————————————————-
To join the audio conference only
Call-in toll number (US/Canada): 1-408-792-6300
Global call-in numbers: https://hms.webex.com/hms/globalcallin.php?serviceType=EC&ED=658503687&tollFree=0
Toll-free dialing restrictions: https://www.webex.com/pdf/tollfree_restrictions.pdf
Access code: 710 073 887
Event password: MULTI
To contact your host, RESIST-TB, please send a message to email@example.com
The playback of UCF (Universal Communications Format) rich media files requires appropriate players. To view this type of rich media files in the meeting, please check whether you have the players installed on your computer by going to https://hms.webex.com/hms/onstage/systemdiagnosis.php
IMPORTANT NOTICE: This WebEx service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.